Research Focus Area:
Health Disparities, Informatics, Diagnosis/ Prognosis
Type of Research:
Research Interest Statement:
I am a bioinformatician that specializes in cancer genomics using Next Generation Sequencing and the integration of heterogeneous datasets. My main focus has been in understanding the genomic and transcriptomic disruption that occurs in Multiple Myeloma and their effects on prognosis. Additionally, I am interested in studying cancer disparities in minority and rural populations.
Schinke C, Poos AM, Bauer MA, [et al.]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single cell level. Blood advances. 2022. PMID: 35977111.
Rasche L, Schinke C, Maura F, [et al., including Bauer MA]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
Ashby C, Boyle EM, Bauer MA, [et al.]. Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood cancer journal. 2022 12(5):85. PMID: 35637217. PMCID: PMC9151656.
Bauer MA, Todorova VK, Stone A, [et al.]. Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer. Cancers. 2021 13(24). PMID: 34944912. PMCID: PMC8699582.
Ghamlouch H, Boyle EM, Blaney P, [et al., including Bauer M]. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. Journal of experimental & clinical cancer research : CR. 2021 40(1):380. PMID: 34857028. PMCID: PMC8638425.
Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Bauer M]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
Boyle EM, Rosenthal A, Wang Y, [et al., including Bauer M]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
Boyle EM, Williams L, Blaney P, [et al., including Bauer M]. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia. 2021. PMID: 34148053.
Stahr S, Chiang TC, Bauer MA, [et al.]. Low?Level Environmental Heavy Metals are Associated with Obesity Among Postmenopausal Women in a Southern State. Exposure and health. 2021 13(2):269-280. PMID: 34337191. PMCID: PMC8323941.
Maura F, Boyle EM, Rustad EH, [et al., including Bauer M]. Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in cell & developmental biology. 2021. PMID: 33958284.
Wardell CP, Ashby C, Bauer MA. FiNGS: high quality somatic mutations using filters for next generation sequencing. BMC bioinformatics. 2021 22(1):77. PMID: 33602113. PMCID: PMC7890800.
Boyle EM, Deshpande S, Tytarenko R, [et al., including Bauer MA]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579.
Danziger SA, McConnell M, Gockley J, [et al., including Bauer M]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
Choudhury SR, Ashby C, Tytarenko R, [et al., including Bauer M]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
Ashby C, Rutherford M, Bauer MA, [et al.]. TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use. BMC bioinformatics. 2020 21(1):144. PMID: 32293247. PMCID: PMC7158102.
Bauer MA, Ashby C, Wardell C, [et al.]. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. 2020. PMID: 32079689.
Boyle EM, Ashby C, Tytarenko R, [et al., including Bauer MA]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
Kiffer F, Alexander T, Anderson J, [et al., including Bauer M]. Late Effects of 1H + 16O on Short-Term and Object Memory, Hippocampal Dendritic Morphology and Mutagenesis. Frontiers in behavioral neuroscience. 2020 14:96. PMID: 32670032. PMCID: PMC7332779.
Rasche L, Alapat D, Kumar M, [et al., including Bauer M]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.
Mikulasova A, Ashby C, Tytarenko RG, [et al., including Bauer MA]. Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma. Haematologica. 2019. PMID: 31221783.
Ashby C, Tytarenko RG, Wang Y, [et al., including Bauer M]. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 10(7):732-737. PMID: 30774775. PMCID: PMC6366829.
Ashby C, Peterson EA, Bauer M, Johann DJ. A Scalable and Adaptive Approach for NGS Analyses Leveraging High-Performance Computing. Pathological Specimens and Genomics Medicine: Emerging Issues. 2019:248.
Walker BA, Mavrommatis K, Wardell CP, [et al., including Bauer M]. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 33(1):159-170. PMID: 29967379. PMCID: PMC6326953.
Boyle EM, Ashby C, Wardell CP, [et al., including Bauer MA]. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018 132(26):2775-2777. PMID: 30446495.
Morgan GJ, He J, Tytarenko R, [et al., including Bauer M]. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 32(11):2435-2444. PMID: 29654269. PMCID: PMC6224403.
Walker BA, Mavrommatis K, Wardell CP, [et al., including Bauer M]. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 132(6):587-597. PMID: 29884741. PMCID: PMC6097138.
Thanendrarajan S, Tian E, Qu P, [et al., including Bauer M]. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 102(9):e364-e367. PMID: 28550191. PMCID: PMC5685226.
Rasche L, Chavan SS, Stephens OW, [et al., including Bauer M]. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature communications. 2017 8(1):268. PMID: 28814763. PMCID: PMC5559527.
Chavan SS, He J, Tytarenko R, [et al., including Bauer M]. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood cancer journal. 2017 7(2):e535. PMID: 28234347. PMCID: PMC5386330.
Weinhold N, Ashby C, Rasche L, [et al., including Bauer MA]. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 128(13):1735-44. PMID: 27516441. PMCID: PMC5043128.